“数据引领药物研发”药渡数据产品发布会将于8月20日举办

2017-08-16 佚名 MedSci原创

北京2017年8月10日电 /美通社/ -- 药渡经纬信息科技(北京)有限公司(简称药渡)将于2017年8月20日下午1时至5时15分在北京新疆大厦举办“数据引领药物研发” 药渡数据产品发布会。在此次发布会上,药渡公司董事长李靖博士和 CEO 丁红霞博士将分享药渡数据在决策医药研发中的重要作用,并介绍“全球新药指数”的概念。药渡公司副总裁梁波博士还将以具体的研发案例来为大家分享数据情报在新药研发中的重要作用。此次活动同时力邀多位行业专家、政府领导、企业高管出席,共同探讨医药行业新药研发创新之路的机遇和挑战,见证药渡的发展。

药渡发布会整体宣传图
药渡发布会整体宣传图

药渡自成立以来,以“助力药物创新、加速价值创造”为使命,全力打造生物医药垂直领域的“一站式信息服务”平台,为生物医药行业提供更有价值的创新产品和专业服务。

欢迎各位业内同行参与本次发布会,参与的企业现场还将获得药渡资讯事业部推出的免费企业服务大礼包及其他惊喜礼包

一、如何报名

  1. 请点击链接提交报名信息:https://www.sojump.hk/jq/15370160.aspx
  2. 或扫描下方二维码提交报名信息
  3. 本次发布会所有参与者可免费参加,药渡将会在8月14日-8月18日之间根据报名信息确认参会嘉宾的资格,收到参会电子券的嘉宾方可参会,请准确提交报名信息。报名问题咨询电话:010-62974355-6030
药渡发布会报名链接
药渡发布会报名链接

 二、部分特邀嘉宾

药渡发布会特邀嘉宾
药渡发布会特邀嘉宾

三、本次活动议程

时间:2017年8月20日下午1时至5时15分

地点:北京新疆大厦三层木卡姆宴会厅

会议议程" border="0" alt="药渡发布会会议议程" align="middle" src="http://photos.prnasia.com/prnvar/20170810/1917716-1-d" />
药渡发布会会议议程

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2052606, encodeId=58e5205260689, content=<a href='/topic/show?id=a78e3e8631a' target=_blank style='color:#2F92EE;'>#发布会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37863, encryptionId=a78e3e8631a, topicName=发布会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Dec 07 07:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300044, encodeId=599e1300044c0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301445, encodeId=78391301445b8, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-12-07 宋威
  2. [GetPortalCommentsPageByObjectIdResponse(id=2052606, encodeId=58e5205260689, content=<a href='/topic/show?id=a78e3e8631a' target=_blank style='color:#2F92EE;'>#发布会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37863, encryptionId=a78e3e8631a, topicName=发布会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Dec 07 07:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300044, encodeId=599e1300044c0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301445, encodeId=78391301445b8, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-18 lqvr
  3. [GetPortalCommentsPageByObjectIdResponse(id=2052606, encodeId=58e5205260689, content=<a href='/topic/show?id=a78e3e8631a' target=_blank style='color:#2F92EE;'>#发布会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37863, encryptionId=a78e3e8631a, topicName=发布会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Dec 07 07:59:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300044, encodeId=599e1300044c0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301445, encodeId=78391301445b8, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Aug 18 04:59:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]